$ENTA
ENANTA PHARMACEUTICALS INC

2023 Q1 Form 10-Q Financial Statement

#000095017023002134 Filed on February 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4
Revenue $17.80M $23.59M
YoY Change -4.92% -14.7%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.78M $12.70M
YoY Change 31.52% 33.53%
% of Gross Profit
Research & Development $43.47M $40.90M
YoY Change 3.28% -15.75%
% of Gross Profit
Depreciation & Amortization $540.0K $511.0K
YoY Change -34.31% -34.49%
% of Gross Profit
Operating Expenses $43.47M $40.90M
YoY Change 3.28% -15.75%
Operating Profit -$39.45M -$30.01M
YoY Change 16.56% -1.3%
Interest Expense $1.837M $993.0K
YoY Change 620.39% 284.88%
% of Operating Profit
Other Income/Expense, Net $1.837M $993.0K
YoY Change 620.39% 284.88%
Pretax Income -$37.61M -$29.02M
YoY Change 11.97% -3.75%
Income Tax $44.00K -$34.00K
% Of Pretax Income
Net Earnings -$37.66M -$28.99M
YoY Change 12.1% -3.75%
Net Earnings / Revenue -211.62% -122.9%
Basic Earnings Per Share -$1.79 -$1.39
Diluted Earnings Per Share -$1.79 -$1.39
COMMON SHARES
Basic Shares Outstanding 20.89M 20.80M
Diluted Shares Outstanding 21.04M 20.82M

Balance Sheet

Concept 2023 Q1 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $210.1M $214.5M
YoY Change -25.06% -17.21%
Cash & Equivalents $73.18M $42.22M
Short-Term Investments $136.9M $172.2M
Other Short-Term Assets $14.48M $17.95M
YoY Change 2.88% 55.97%
Inventory
Prepaid Expenses
Receivables $17.80M $22.59M
Other Receivables $28.77M $28.70M
Total Short-Term Assets $271.1M $283.7M
YoY Change -20.69% -13.23%
LONG-TERM ASSETS
Property, Plant & Equipment $11.05M $8.682M
YoY Change 129.49% 59.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $15.04M $26.94M
YoY Change -64.38% -69.62%
Other Assets $696.0K $701.0K
YoY Change 656.52% 661.96%
Total Long-Term Assets $55.31M $63.83M
YoY Change -14.84% -43.83%
TOTAL ASSETS
Total Short-Term Assets $271.1M $283.7M
Total Long-Term Assets $55.31M $63.83M
Total Assets $326.4M $347.5M
YoY Change -19.76% -21.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.76M $4.352M
YoY Change 96.51% -44.5%
Accrued Expenses $15.48M $15.16M
YoY Change -28.79% -42.95%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $32.17M $23.00M
YoY Change 4.65% -39.3%
LONG-TERM LIABILITIES
Long-Term Debt $1.423M $1.423M
YoY Change -5.51% -5.51%
Other Long-Term Liabilities $408.0K $414.0K
YoY Change -53.42% -51.64%
Total Long-Term Liabilities $408.0K $414.0K
YoY Change -53.42% -51.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.17M $23.00M
Total Long-Term Liabilities $408.0K $414.0K
Total Liabilities $57.07M $46.70M
YoY Change 18.32% -16.92%
SHAREHOLDERS EQUITY
Retained Earnings -$139.8M -$102.2M
YoY Change 824.08% -653.41%
Common Stock $411.0M $405.7M
YoY Change 9.09% 10.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $269.4M $300.8M
YoY Change
Total Liabilities & Shareholders Equity $326.4M $347.5M
YoY Change -19.76% -21.12%

Cashflow Statement

Concept 2023 Q1 2022 Q4
OPERATING ACTIVITIES
Net Income -$37.66M -$28.99M
YoY Change 12.1% -3.75%
Depreciation, Depletion And Amortization $540.0K $511.0K
YoY Change -34.31% -34.49%
Cash From Operating Activities -$13.78M -$35.64M
YoY Change -47.74% 168.56%
INVESTING ACTIVITIES
Capital Expenditures $2.383M $3.156M
YoY Change -3320.27% 769.42%
Acquisitions
YoY Change
Other Investing Activities $49.15M $36.73M
YoY Change -240.5% -19.93%
Cash From Investing Activities $46.77M $33.57M
YoY Change -233.4% -26.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.027M 301.0K
YoY Change -160.49% -96.88%
NET CHANGE
Cash From Operating Activities -13.78M -35.64M
Cash From Investing Activities 46.77M 33.57M
Cash From Financing Activities -2.027M 301.0K
Net Change In Cash 30.96M -1.771M
YoY Change -153.3% -104.23%
FREE CASH FLOW
Cash From Operating Activities -$13.78M -$35.64M
Capital Expenditures $2.383M $3.156M
Free Cash Flow -$16.17M -$38.80M
YoY Change -38.53% 184.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2022Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001177648
CY2022Q4 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 dei Document Type
DocumentType
10-Q
CY2022Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q4 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q4 dei Entity File Number
EntityFileNumber
001-35839
CY2022Q4 dei Entity Registrant Name
EntityRegistrantName
ENANTA PHARMACEUTICALS, INC
CY2022Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3205099
CY2022Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
500 Arsenal Street
CY2022Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
CY2022Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
CY2022Q4 dei City Area Code
CityAreaCode
617
CY2022Q4 dei Local Phone Number
LocalPhoneNumber
607-0800
CY2022Q4 dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
CY2022Q4 dei Trading Symbol
TradingSymbol
ENTA
CY2022Q4 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q4 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q4 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q4 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20886433
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42223000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43994000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
172247000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
205238000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
17946000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13445000
CY2022Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
28703000
CY2022Q3 us-gaap Income Tax Receivable
IncomeTaxReceivable
28718000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
283704000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
311713000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
26939000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
29285000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8682000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6173000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23540000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23575000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3968000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
22585000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
20318000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3968000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
701000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
696000
CY2022Q4 us-gaap Assets
Assets
347534000
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-30013000
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-30409000
CY2022Q3 us-gaap Assets
Assets
375410000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4352000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6000000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15163000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20936000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3486000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2891000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23001000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
29827000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21859000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22372000
CY2022Q4 enta Non Convertible Preferred Stock Liabilities
NonConvertiblePreferredStockLiabilities
1423000
CY2022Q3 enta Non Convertible Preferred Stock Liabilities
NonConvertiblePreferredStockLiabilities
1423000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
414000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
454000
CY2022Q4 us-gaap Liabilities
Liabilities
46697000
CY2022Q3 us-gaap Liabilities
Liabilities
54076000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20884000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20884000
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20791000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20791000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
209000
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
208000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
405468000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
398029000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2675000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3724000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102165000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-73179000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
300837000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
321334000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
347534000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
375410000
CY2022Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
23585000
CY2021Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27648000
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40902000
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48549000
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12696000
CY2021Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9508000
CY2022Q4 us-gaap Costs And Expenses
CostsAndExpenses
53598000
CY2021Q4 us-gaap Costs And Expenses
CostsAndExpenses
58057000
CY2022Q4 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
993000
CY2021Q4 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
258000
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
993000
CY2021Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
258000
CY2021Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4072000
CY2022Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4501000
CY2021Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2682000
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29020000
CY2021Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30151000
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-34000
CY2021Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-36000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-28986000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-30115000
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.39
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.39
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.48
CY2021Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.48
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20816000
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20816000
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20388000
CY2021Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20388000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-28986000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-30115000
CY2022Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1049000
CY2021Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-624000
CY2022Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1049000
CY2021Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-624000
CY2022Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27937000
CY2021Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30739000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
321334000
CY2022Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1126000
CY2022Q4 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-825000
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7139000
CY2022Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1049000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-28986000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
300837000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
399429000
CY2021Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10409000
CY2021Q4 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-777000
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6062000
CY2021Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-624000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-30115000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
384384000
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-28986000
CY2021Q4 us-gaap Profit Loss
ProfitLoss
-30115000
CY2022Q4 us-gaap Share Based Compensation
ShareBasedCompensation
7139000
CY2021Q4 us-gaap Share Based Compensation
ShareBasedCompensation
6062000
CY2022Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
511000
CY2021Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
780000
CY2022Q4 enta Premium On Marketable Securities
PremiumOnMarketableSecurities
0
CY2021Q4 enta Premium On Marketable Securities
PremiumOnMarketableSecurities
474000
CY2022Q4 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
339000
CY2021Q4 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-546000
CY2022Q4 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-15000
CY2021Q4 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-8504000
CY2022Q4 enta Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-834000
CY2021Q4 enta Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-1436000
CY2022Q4 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
5000
CY2022Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2267000
CY2021Q4 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
CY2022Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-686000
CY2021Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1663000
CY2022Q4 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6599000
CY2021Q4 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4206000
CY2022Q4 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-717000
CY2021Q4 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1461000
CY2022Q4 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-40000
CY2021Q4 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
298000
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35641000
CY2021Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13271000
CY2022Q4 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
67375000
CY2021Q4 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
62902000
CY2022Q4 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
104100000
CY2021Q4 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
108766000
CY2022Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3156000
CY2021Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
363000
CY2022Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
33569000
CY2021Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
45501000
CY2022Q4 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1126000
CY2021Q4 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10409000
CY2022Q4 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
825000
CY2021Q4 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
777000
CY2022Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
301000
CY2021Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9632000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1771000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
41862000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47962000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
57814000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
46191000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
99676000
CY2022Q4 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1079000
CY2021Q4 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
46000
CY2022Q4 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
799000
CY2021Q4 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
15559000
CY2022Q4 us-gaap Year Founded
YearFounded
1995
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-28986000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-121755000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102165000
CY2022Q4 enta Cash Cash Equivalents Short Term And Long Term Marketable Securities
CashCashEquivalentsShortTermAndLongTermMarketableSecurities
241.4
CY2022Q4 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, management’s judgments with respect to its revenue arrangements; valuation of stock-based awards and the accrual of research and development expenses. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. The future developments of the COVID-19 pandemic also may directly or indirectly impact the Company’s business. The Company has made estimates of the impact of COVID-19 in the Company’s consolidated financial statements as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Actual results could differ from the Company’s estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
220477000
CY2022Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1423000
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
248428000
CY2022Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1423000
CY2022Q4 enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2021Q4 enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
201477000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2291000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
199186000
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
237863000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3340000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
234523000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
26939000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
29285000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
53.57
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M12D
CY2022Q4 enta Accrued Liabilities Manufacturing
AccruedLiabilitiesManufacturing
3828000
CY2022Q3 enta Accrued Liabilities Manufacturing
AccruedLiabilitiesManufacturing
6932000
CY2022Q4 enta Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
6862000
CY2022Q3 enta Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
5532000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2593000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6439000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1880000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2033000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15163000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20936000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3993000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
28778000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
618000
CY2022Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
44.89
CY2022Q4 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
56000
CY2022Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
20.25
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
44000
CY2022Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
74.31
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4511000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
52.59
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
17648000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4511000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
52.59
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y7M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
17648000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2685000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
50.75
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y1M6D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
15547000
CY2022Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7139000
CY2021Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6062000
CY2022Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7139000
CY2021Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6062000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
79225000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D

Files In Submission

Name View Source Status
0000950170-23-002134-index-headers.html Edgar Link pending
0000950170-23-002134-index.html Edgar Link pending
0000950170-23-002134.txt Edgar Link pending
0000950170-23-002134-xbrl.zip Edgar Link pending
enta-20221231.htm Edgar Link pending
enta-20221231.xsd Edgar Link pending
enta-ex31_1.htm Edgar Link pending
enta-ex31_2.htm Edgar Link pending
enta-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img215141716_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
enta-20221231_lab.xml Edgar Link unprocessable
enta-20221231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
enta-20221231_htm.xml Edgar Link completed
enta-20221231_cal.xml Edgar Link unprocessable
enta-20221231_def.xml Edgar Link unprocessable